In a highdose semaglutide trial (7.2 mg weekly), participants lost about 20.7% of body weight in 72 weeks, with a substantial portion achieving up to 25% weight loss
While some peptides are FDA-approved for weight loss, others require careful monitoring
The reduction in hepatic steatosis occurred alongside improvements in liver enzymes, with ALT and AST levels declining from baseline, indicating reduced hepatocellular inflammation and improved liver health
The options for action provided answer questions about different interventions with corresponding recommendations for decision support and, if necessary, alternative futures as a consequence
Some Injuries Remain in Limbo Many people who have suffered injuries from GLP-1 drugs have joined a multidistrict lawsuit (MDL) called MDL 3094: In Re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAS) Products Liability Litigation
Step 2: Demand Third-Party Lab Reports Never purchase a research peptide without independent verification of its purity
